Evidence map›Paper›PMID 36830041›Full record

ArticleAntioxidants (Basel, Switzerland)2023

How the Competition for Cysteine May Promote Infection of SARS-CoV-2 by Triggering Oxidative Stress.

Annamaria Vernone, Loredana Bergandi, Simone Pernice, Gianpiero Pescarmona, Francesca Silvagno

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Annamaria VernoneDepartment of Neurosciences "Rita Levi Montalcini", University of Torino, Via Cherasco 15, 10126 Torino, Italy.ORCID 0000-0002-9748-2178
Loredana BergandiDepartment of Oncology, University of Torino, Via Santena 5 bis, 10126 Torino, Italy.ORCID 0000-0003-0951-7340
Simone PerniceDepartment of Computer Science, University of Torino, Via Pessinetto 12, 10149 Torino, Italy.ORCID 0000-0001-7124-4676
Gianpiero PescarmonaDepartment of Oncology, University of Torino, Via Santena 5 bis, 10126 Torino, Italy.
Francesca SilvagnoDepartment of Oncology, University of Torino, Via Santena 5 bis, 10126 Torino, Italy.ORCID 0000-0002-8800-9135
University of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 induces a broad range of clinical manifestations. Besides the main receptor, ACE2, other putative receptors and co-receptors have been described and could become genuinely relevant to explain the different tropism manifested by new variants. In this study, we propose a biochemical model envisaging the competition for cysteine as a key mechanism promoting the infection and the selection of host receptors. The SARS-CoV-2 infection produces ROS and triggers a massive biosynthesis of proteins rich in cysteine; if this amino acid becomes limiting, glutathione levels are depleted and cannot control oxidative stress. Hence, infection succeeds. A receptor should be recognized as a marker of suitable intracellular conditions, namely the full availability of amino acids except for low cysteine. First, we carried out a comparative investigation of SARS-CoV-2 proteins and human ACE2. Then, using hierarchical cluster protein analysis, we searched for similarities between all human proteins and spike produced by the latest variant, Omicron BA.1. We found 32 human proteins very close to spike in terms of amino acid content. Most of these potential SARS-CoV-2 receptors have less cysteine than spike. We suggest that these proteins could signal an intracellular shortage of cysteine, predicting a burst of oxidative stress when used as viral entry mediators.

Indexed as

ACE2amino acid availabilitycysteineglutathioneROSSARS-CoV-2SARS-CoV-2 receptorspike

Identifiers

PMID36830041
PMCPMC9952211
OpenAlexW4320918638

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.